Trial reportBritish journal of cancer2005
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Trial report in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00006476 (A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- HMGA2 Overexpression in Papillary Thyroid Cancer Promotes Thyroid Cell Dedifferentiation and Invasion, and These Effects Are Counteracted by Suramin.International journal of molecular sciences · 2025Article
- The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics.Journal of oncology research and therapy · 2024Article
- Old Polyanionic Drug Suramin Suppresses Detrimental Cytotoxicity of the Host Defense Peptide LL-37.ACS pharmacology & translational science · 2021Article
- 100 Years of Suramin.Antimicrobial agents and chemotherapy · 2020Review
- Review
- SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects.PloS one · 2014Article
- Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.The AAPS journal · 2010Article
- Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.Open access journal of urology · 2010Review
- New therapies for non-muscle-invasive bladder cancer.World journal of urology · 2010Review
- Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients.American journal of physiology. Renal physiology · 2008Article
- Intravesical treatments of bladder cancer: review.Pharmaceutical research · 2008Review
- Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.Journal of cellular biochemistry · 2008Review
- Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.International journal of clinical oncology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an open-labelled, non-randomized dose-escalation phase I study. In all, 12 patients with a history of recurrent superficial bladder cancer were grouped into four dose levels (10-150 mg ml(-1) in 60 ml saline). Six catheter instillations at weekly intervals were used. Cystoscopy and biopsy were performed before and 3 months after the start of treatment. Suramin was assayed using high-performance liquid chromatography, vascular endothelial growth factor (VEGF) using ELISA (enzyme-linked immunosorbent assay), and urinary protein profile using surface-enhanced laser desorption ionisation mass spectroscopy (SELDI). Minimal systemic absorption of Suramin was found at the highest dose of 150 mg ml(-1). Urinary VEGF was affected by Suramin at doses above 50 mg ml(-1), corresponding to the estimated threshold of saturation of Suramin binding to urine albumin. SELDI showed a specific disappearance of urinary protein peaks during treatment. Intravesical Suramin shows lack of toxicity and low systemic absorption. The results of this phase I trial support expanded clinical trials of efficacy at a dose of 100 mg ml(-1) intravesically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.